Investigator Initiated Research (IIR) Program

Exosome Diagnostics, a division of Bio-Techne Corporation, is committed to advancing medical and scientific learning about our biomarkers and assays for improving patient care via support of Investigator Initiated Research Grants.

This program is open to all U.S. physicians, scientists and institutions who are interested in conducting their own clinical and basic science research that address important medical and scientific questions related to our products and our research areas of interest.

Exosome Diagnostics may provide support in the form of assays and/or financial support in response to unsolicited, independent research proposals that meet our high standards of quality and compliance.

Investigator Initiated research is conducted independent of Exosome Diagnostics. The Principal Investigator (PI) or the institution serves as the Sponsor of the research and is responsible for study conception, design, conduct, data handling, data analysis/interpretation, subsequent reporting/publication and ensuring compliance with all legal and regulatory responsibilities of the studies as defined by all applicable laws and regulations.

These proposals are reviewed by an Exosome committee of medical and scientific staff (see Exosome Review Committee composition). Decisions for support are strictly based on scientific merit, feasibility, safety, legal and ethical considerations, and alignment with Exosome’s research area of interest and availability of resources and funds. Exosome support for any Independent Investigator Initiated Research Grants in no way implies any obligation toward, and is not in any way connected to, the recommendation or prescribing of Exosome products.

Current research areas of interest focus on prostate cancer, bladder cancer, and additional areas related to exosome-based biomarkers. Some areas of interest included but are not limited to ExoDx™ Prostate integration with imaging modalities, ExoDx Prostate utility for new indications, resource utilization and potential EPI clinical utility for new indications.